Delving into the Latest Updates on UFR2709 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

nAChRα4&β2

Mechanism

nAChRα4&β2 antagonists(Neuronal acetylcholine receptor; alpha4/beta2 antagonists)

Therapeutic Areas

Other Diseases

Active Indication

Alcoholism

Inactive Indication-

Originator Organization

University of Chile

Active Organization

University of Chile

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure

Molecular FormulaC13H17NO2

InChIKeyPXVQMUATEFMGFD-LBPRGKRZSA-N

CAS Registry1431628-22-6

Zebrafish is becoming a popular animal model in neuropharmacology and drug discovery, mainly due to its ease of handling and low costs involved in maintenance and experimental work. This animal displays a series of complex behaviours that makes it useful for assessing the effects of psychoactive drugs. Here, adult zebrafish were used for assessment of the anxiolytic and anti-addictive properties of UFR2709, a nicotinic receptor (nAChR) antagonist, using two behavioural paradigms to test for addiction, the novel tank diving test to assess anxiety and the conditioned place preference (CPP). Furthermore, the expression of nAChR subunits α4 and α7 was measured in the zebrafish brain. The results show that UFR2709 exhibits an anxiolytic effect on zebrafish and blocks the effect evoked by nicotine on CPP. Moreover, UFR2709 significantly decreased the expression of α4 nicotinic receptor subunit. This indicates that UFR2709 might be a useful drug for the treatment of nicotine addiction.

100 Deals associated with UFR2709

Login to view more data